PRODUCT HIGHLIGHTS

• MAXON™ and MAXON™ CV synthetic absorbable sutures are prepared from polyglyconate, a copolymer of glycolic acid and trimethylene carbonate
  
  
• MAXON™ and MAXON™ CV synthetic absorbable sutures are indicated for use in general soft tissue approximation and/or ligation, including use in pediatric cardiovascular tissue, where growth is expected to occur, and in peripheral vascular surgery
  
  
• MAXON™ and MAXON™ CV synthetic absorbable sutures are not indicated for use in adult cardiovascular tissue, ophthalmic surgery, microsurgery and neural tissues
  
  
• MAXON™ sutures retain approximately 75% of initial tensile strength at two weeks, 65% of at three weeks and 50% at four weeks post-implant
  
  
• Absorption of MAXON™ sutures is minimal until about 60 days after implant and is essentially complete within six months